Privately held biopharmaceutical company developing first-in-class therapeutics that target myosin molecular motor proteins
Privately held biopharmaceutical company developing first-in-class therapeutics that target myosin molecular motor proteins. Its proprietary nMotor platform supports drug discovery and screening. Lead clinical program MT-125 is a dual inhibitor of non-muscle myosin IIA/IIB being developed for glioblastoma and other cancers; the company is also developing neurotherapeutics for substance use disorders.